巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Sight Sciences

    SGHT
    8.790
    0.660
    8.12%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Sight Sciences - 延遲價格・最後更新於 27/05 12:14
    最高位
    8.890
    最低位
    7.990
    開市價
    --
    前收市價
    8.130
    成交量(千)
    16.57
    成交額(百萬)
    1.27
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    418.32
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    39.730 - 6.250
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Sight Sciences
    證券代碼
    SGHT.US
    所屬板塊
    Medical Devices
    公司業務
    Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
    發行量
    47586682
    公司總部
    4040 Campbell Avenue, Suite 100
    公司網址
    https://www.sightsciences.com
    公司電話
    +1 877 266-1144

    美股收盤漲跌不一 本周三大股指均錄得漲幅|美股收盤

    辛海棠·
    美股收盤漲跌不一 本周三大股指均錄得漲幅|美股收盤

    眼科醫療器械供應商Sight Sciences上市首日漲超30%

    李進·
    眼科醫療器械供應商Sight Sciences上市首日漲超30%

    關於

    Sight Sciences(SGHT.US)所屬的行業板塊為Medical Devices。
    Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
    詳細公司背景可參考: https://www.sightsciences.com